Apellis Pharmaceuticals, Inc. APLS
We take great care to ensure that the data presented and summarized in this overview for Apellis Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding APLS
View all-
Wellington Management Group LLP Boston, MA15.1MShares$614 Million0.16% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.4MShares$463 Million19.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$453 Million7.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.51MShares$387 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$224 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.61MShares$188 Million0.17% of portfolio
-
Jennison Associates LLC3.24MShares$132 Million0.13% of portfolio
-
State Street Corp Boston, MA2.91MShares$119 Million0.01% of portfolio
-
Octagon Capital Advisors LP New York, NY2.81MShares$114 Million25.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.46MShares$100 Million0.02% of portfolio
Latest Institutional Activity in APLS
Top Purchases
Top Sells
About APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Insider Transactions at APLS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 20
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,500
+2.1%
|
$73,500
$3.76 P/Share
|
May 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
78,907
-2.23%
|
$3,393,001
$43.01 P/Share
|
May 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
78,907
+6.19%
|
$315,628
$4.31 P/Share
|
Apr 18
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
14,164
+16.75%
|
-
|
Apr 18
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
14,164
-15.18%
|
-
|
Apr 12
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.11%
|
$19,500
$13.19 P/Share
|
Apr 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
69,107
-2.93%
|
$3,731,778
$54.52 P/Share
|
Apr 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,107
+5.51%
|
$207,321
$3.76 P/Share
|
Apr 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,000
-4.11%
|
$232,000
$58.66 P/Share
|
Apr 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.95%
|
$40,000
$10.03 P/Share
|
Mar 19
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
18,681
-9.7%
|
$1,064,817
$57.18 P/Share
|
Mar 18
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
9,913
-15.34%
|
$555,128
$56.9 P/Share
|
Mar 15
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
184
-0.47%
|
$10,304
$56.46 P/Share
|
Mar 13
2024
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
11,220
-8.64%
|
$639,540
$57.72 P/Share
|
Mar 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
69,107
-1.97%
|
$4,284,634
$62.64 P/Share
|
Mar 08
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,107
+5.51%
|
$207,321
$3.67 P/Share
|
Mar 06
2024
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,762
+3.39%
|
$48,906
$13.85 P/Share
|
Mar 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-3.06%
|
$378,000
$63.41 P/Share
|
Mar 01
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+5.7%
|
$60,000
$10.03 P/Share
|
Mar 01
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
250,000
-10.56%
|
$16,000,000
$64.01 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 276K shares |
---|---|
Exercise of conversion of derivative security | 1.31M shares |
Bona fide gift | 177K shares |
Open market or private sale | 1.16M shares |
---|---|
Bona fide gift | 177K shares |